માથા અને ગરદનનું કેન્સર
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
ક્યાં જવું
ભારતમાં 1 હોસ્પિટલ આ trial માટે દર્દીઓ લઈ રહી છે.
રજિસ્ટ્રી સમરી (ટેકનિકલ)
This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy. A total of approximately 46 male and female patients will be enrolled. This sample size is based on Simon's 2-stage design with historical control ORR of 30% and a target ORR of 50%.
Sponsor: NATCO Pharma Ltd.
ClinicalTrials.gov પર NCT05283226
રજિસ્ટ્રીમાં છેલ્લે 23 Jan 2026 ના અપડેટ થયું · અમે 20 Oct 2026 ના વાંચ્યું